



REPORTED SALES vs. PRIOR PERIOD

\$MM

	THIRD QUARTER					NINE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
Reported			Operational ⁽¹⁾	Currency	Reported			Operational ⁽¹⁾	Currency	
PHARMACEUTICAL SEGMENT ⁽²⁾										
<u>ACIPHEX/PARIET</u>										
US	159	146	8.4%	8.4%	-	479	438	9.3%	9.3%	-
Intl	179	161	11.6%	4.0%	7.6%	531	483	9.9%	3.4%	6.5%
WW	338	307	10.1%	6.1%	4.0%	1,010	921	9.7%	6.3%	3.4%
<u>Anti-Psychotics ⁽³⁾</u>										
US	674	635	6.3%	6.3%	-	2,037	1,788	13.9%	13.9%	-
Intl	488	433	12.8%	5.6%	7.2%	1,440	1,334	7.9%	1.8%	6.1%
WW	1,162	1,068	8.9%	6.0%	2.9%	3,477	3,122	11.4%	8.8%	2.6%
<u>CONCERTA</u>										
US	177	179	-1.2%	-1.2%	-	576	547	5.3%	5.3%	-
Intl	54	41	34.0%	24.8%	9.2%	163	125	30.5%	22.4%	8.1%
WW	231	220	5.3%	3.6%	1.7%	739	672	10.0%	8.5%	1.5%
<u>DURAGESIC</u>										
US	107	138	-23.0%	-23.0%	-	319	369	-13.8%	-13.8%	-
Intl	202	204	-0.7%	-6.5%	5.8%	581	633	-8.2%	-13.2%	5.0%
WW	309	342	-9.7%	-13.2%	3.5%	900	1,002	-10.2%	-13.4%	3.2%
<u>EPREX/PROCRIT</u>										
US	380	522	-27.1%	-27.1%	-	1,359	1,573	-13.6%	-13.6%	-
Intl	302	276	9.0%	1.0%	8.0%	898	819	9.6%	2.2%	7.4%
WW	682	798	-14.6%	-17.4%	2.8%	2,257	2,392	-5.6%	-8.1%	2.5%
<u>Hormonal Contraceptives</u>										
US	166	210	-21.2%	-21.2%	-	516	597	-13.7%	-13.7%	-
Intl	67	60	11.9%	4.1%	7.8%	194	175	11.3%	5.0%	6.3%
WW	233	270	-13.9%	-15.6%	1.7%	710	772	-8.0%	-9.4%	1.4%
<u>LEVAQUIN/FLOXIN</u>										
US	352	334	5.4%	5.4%	-	1,155	1,048	10.2%	10.2%	-
Intl	19	13	46.2%	42.9%	3.8%	59	43	37.2%	36.5%	0.7%
WW	371	347	6.9%	6.8%	0.1%	1,214	1,091	11.2%	11.2%	-
<u>REMICADE</u>										
US	648	602	7.5%	7.5%	-	1,873	1,763	6.3%	6.3%	-
Intl	171	174	-1.4%	-1.4%	-	546	470	16.1%	16.1%	-
WW	819	776	5.5%	5.5%	-	2,419	2,233	8.3%	8.3%	-
<u>TOPAMAX</u>										
US	498	435	14.4%	14.4%	-	1,471	1,200	22.5%	22.5%	-
Intl	115	98	17.5%	9.7%	7.8%	330	298	10.9%	4.0%	6.9%
WW	613	533	15.0%	13.6%	1.4%	1,801	1,498	20.2%	18.8%	1.4%
<u>Other</u>										
US	604	640	-5.6%	-5.6%	-	1,874	1,901	-1.4%	-1.4%	-
Intl	737	580	27.1%	18.1%	9.0%	2,068	1,713	20.7%	13.1%	7.6%
WW	1,341	1,220	9.9%	5.6%	4.3%	3,942	3,614	9.1%	5.5%	3.6%
<u>Total Pharmaceutical</u>										
US	3,765	3,841	-2.0%	-2.0%	-	11,659	11,224	3.9%	3.9%	-
Intl	2,334	2,040	14.4%	7.2%	7.2%	6,810	6,093	11.8%	5.6%	6.2%
WW	6,099	5,881	3.7%	1.2%	2.5%	18,469	17,317	6.7%	4.5%	2.2%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ Includes Risperdal, Risperdal Consta & Invega



REPORTED SALES vs. PRIOR PERIOD

\$MM

	THIRD QUARTER					NINE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS⁽²⁾										
<u>Cordis</u>										
US	373	502	-25.6%	-25.6%	-	1,194	1,569	-23.9%	-23.9%	-
Intl	404	481	-16.3%	-20.7%	4.4%	1,363	1,557	-12.5%	-15.8%	3.3%
WW	777	983	-21.0%	-23.1%	2.1%	2,557	3,126	-18.2%	-19.9%	1.7%
<u>DePuy</u>										
US	636	605	5.2%	5.2%	-	1,977	1,892	4.5%	4.5%	-
Intl	450	366	22.9%	14.6%	8.3%	1,401	1,153	21.5%	13.9%	7.6%
WW	1,086	971	11.9%	8.8%	3.1%	3,378	3,045	10.9%	8.0%	2.9%
<u>Ethicon</u>										
US	349	326	7.2%	7.2%	-	1,043	943	10.6%	10.6%	-
Intl	528	470	12.1%	4.7%	7.4%	1,605	1,443	11.2%	4.8%	6.4%
WW	877	796	10.1%	5.7%	4.4%	2,648	2,386	11.0%	7.1%	3.9%
<u>Ethicon Endo-Surgery</u>										
US	440	416	5.8%	5.8%	-	1,311	1,212	8.2%	8.2%	-
Intl	482	409	17.7%	10.9%	6.8%	1,459	1,264	15.4%	9.4%	6.0%
WW	922	825	11.7%	8.3%	3.4%	2,770	2,476	11.9%	8.9%	3.0%
<u>LifeScan</u>										
US	321	278	15.3%	15.3%	-	923	857	7.7%	7.7%	-
Intl	264	227	16.8%	9.0%	7.8%	807	675	19.6%	12.5%	7.1%
WW	585	505	16.0%	12.5%	3.5%	1,730	1,532	13.0%	9.9%	3.1%
<u>Ortho-Clinical Diagnostics</u>										
US	219	184	18.7%	18.7%	-	653	568	14.9%	14.9%	-
Intl	185	176	5.4%	-0.2%	5.6%	550	530	3.7%	-1.2%	4.9%
WW	404	360	12.2%	9.5%	2.7%	1,203	1,098	9.5%	7.2%	2.3%
<u>Total Vision Care</u>										
US	214	185	15.1%	15.1%	-	622	541	15.0%	15.0%	-
Intl	363	308	18.5%	15.7%	2.8%	1,021	867	17.8%	16.1%	1.7%
WW	577	493	17.2%	15.5%	1.7%	1,643	1,408	16.7%	15.7%	1.0%
<u>Other</u>										
US	17	13	30.8%	30.8%	-	49	37	32.4%	32.4%	-
Intl	3	4	-25.0%	-28.0%	3.0%	8	8	-	-2.5%	2.5%
WW	20	17	17.6%	16.9%	0.7%	57	45	26.7%	26.0%	0.7%
<u>Total Medical Devices and Diagnostics</u>										
US	2,569	2,509	2.4%	2.4%	-	7,772	7,619	2.0%	2.0%	-
Intl	2,679	2,441	9.8%	3.7%	6.1%	8,214	7,497	9.6%	4.3%	5.3%
WW	5,248	4,950	6.0%	3.0%	3.0%	15,986	15,116	5.8%	3.2%	2.6%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)



REPORTED SALES vs. PRIOR PERIOD

\$MM

	THIRD QUARTER					NINE MONTHS				
	2007	2006	% Change			2007	2006	% Change		
Reported			Operational ⁽¹⁾	Currency	Reported			Operational ⁽¹⁾	Currency	
CONSUMER SEGMENT ^{(2) (3)}										
<u>Skin Care</u>										
US	311	265	17.2%	17.2%	-	1,006	863	16.5%	16.5%	-
Intl	426	370	15.1%	7.9%	7.2%	1,252	1,085	15.4%	9.0%	6.4%
WW	737	635	16.0%	11.8%	4.2%	2,258	1,948	15.9%	12.3%	3.6%
<u>Baby & Kids Care</u>										
US	113	102	10.3%	10.3%	-	328	302	8.5%	8.5%	-
Intl	398	349	14.2%	6.4%	7.8%	1,117	977	14.4%	8.0%	6.4%
WW	511	451	13.3%	7.3%	6.0%	1,445	1,279	13.0%	8.1%	4.9%
<u>Oral Care</u>										
US	211	58	265.3%	265.3%	-	600	178	236.7%	236.7%	-
Intl	185	38	383.5%	376.1%	7.4%	509	115	342.2%	336.4%	5.8%
WW	396	96	312.3%	309.3%	3.0%	1,109	293	278.1%	275.8%	2.3%
<u>OTC/Nutritionals</u>										
US	653	481	36.0%	36.0%	-	1,892	1,340	41.3%	41.3%	-
Intl	611	218	179.9%	172.5%	7.4%	1,835	645	184.4%	177.7%	6.7%
WW	1,264	699	80.9%	78.6%	2.3%	3,727	1,985	87.8%	85.6%	2.2%
<u>Women's Health</u>										
US	149	151	-1.4%	-1.4%	-	475	448	6.1%	6.1%	-
Intl	312	281	11.2%	3.0%	8.2%	870	798	9.0%	2.2%	6.8%
WW	461	432	6.8%	1.5%	5.3%	1,345	1,246	8.0%	3.7%	4.3%
<u>Other</u>										
US	154	81	90.1%	90.1%	-	481	260	85.0%	85.0%	-
Intl	100	62	61.3%	53.3%	8.0%	318	198	60.6%	54.4%	6.2%
WW	254	143	77.6%	74.2%	3.4%	799	458	74.5%	71.8%	2.7%
<u>Total Consumer</u>										
US	1,591	1,138	39.8%	39.8%	-	4,782	3,391	41.0%	41.0%	-
Intl	2,032	1,318	54.2%	46.5%	7.7%	5,901	3,818	54.6%	48.1%	6.5%
WW	3,623	2,456	47.5%	43.4%	4.1%	10,683	7,209	48.2%	44.8%	3.4%

⁽¹⁾ Operational growth excludes the effect of currency

⁽²⁾ Select areas (unaudited)

⁽³⁾ 2007 Includes sales from acquisition of PCH